Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections

Aaron N. Pham, Joseph Bubalo, James S. Lewis

    Research output: Contribution to journalArticle

    26 Citations (Scopus)

    Abstract

    Posaconazole tablet formulation (PTF) was developed to optimise bioavailability. This study compared posaconazole levels between patients on the PTF and oral suspension formulation (OSF). We also examined factors that may impact posaconazole levels. The primary and secondary objectives were analysed by comparing trough levels and attainment of target level between the formulation groups. For the 86 patients on PTF and 176 on OSF, the mean first levels was 1.32 μg ml-1 (SD = 0.69) and 0.81 μg ml-1 (SD = 0.59), P <0.0001 respectively. PTF group was more likely to achieve levels ≥0.7 μg ml-1 than OSF group (OR 7.97 [95 CI; 3.75-16.93], P <0.0001). Levels from patients on PTF and with presence of acid suppression, GI GVHD, mucositis or diarrhoea were not statistically different from those without these factors. For PTF, no correlation was found between patient's weight (kg) and levels (R2 = 0.0536, P = 0.035). The incidences of elevation in ALT/AST or Tbili were similar between the formulation groups. In conclusion, PTF should be considered the preferred formulation because it demonstrated better absorption than the OSF. Patients on PTF for prophylaxis are more likely to attain target level and may not routinely require therapeutic drug monitoring during prophylaxis.

    Original languageEnglish (US)
    Pages (from-to)226-233
    Number of pages8
    JournalMycoses
    Volume59
    Issue number4
    DOIs
    StatePublished - Apr 1 2016

    Fingerprint

    Tablets
    Suspensions
    Serum
    Neoplasms
    Therapeutics
    posaconazole
    Invasive Fungal Infections
    Mucositis
    Drug Monitoring
    Biological Availability
    Diarrhea
    Weights and Measures
    Acids
    Incidence

    Keywords

    • Acute myeloid leukaemia
    • Antifungal prophylaxis
    • Therapeutic drug monitoring
    • Triazole antifungals

    ASJC Scopus subject areas

    • Dermatology
    • Infectious Diseases

    Cite this

    Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. / Pham, Aaron N.; Bubalo, Joseph; Lewis, James S.

    In: Mycoses, Vol. 59, No. 4, 01.04.2016, p. 226-233.

    Research output: Contribution to journalArticle

    @article{805347c9585645c7b665f518d3efaee2,
    title = "Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections",
    abstract = "Posaconazole tablet formulation (PTF) was developed to optimise bioavailability. This study compared posaconazole levels between patients on the PTF and oral suspension formulation (OSF). We also examined factors that may impact posaconazole levels. The primary and secondary objectives were analysed by comparing trough levels and attainment of target level between the formulation groups. For the 86 patients on PTF and 176 on OSF, the mean first levels was 1.32 μg ml-1 (SD = 0.69) and 0.81 μg ml-1 (SD = 0.59), P <0.0001 respectively. PTF group was more likely to achieve levels ≥0.7 μg ml-1 than OSF group (OR 7.97 [95 CI; 3.75-16.93], P <0.0001). Levels from patients on PTF and with presence of acid suppression, GI GVHD, mucositis or diarrhoea were not statistically different from those without these factors. For PTF, no correlation was found between patient's weight (kg) and levels (R2 = 0.0536, P = 0.035). The incidences of elevation in ALT/AST or Tbili were similar between the formulation groups. In conclusion, PTF should be considered the preferred formulation because it demonstrated better absorption than the OSF. Patients on PTF for prophylaxis are more likely to attain target level and may not routinely require therapeutic drug monitoring during prophylaxis.",
    keywords = "Acute myeloid leukaemia, Antifungal prophylaxis, Therapeutic drug monitoring, Triazole antifungals",
    author = "Pham, {Aaron N.} and Joseph Bubalo and Lewis, {James S.}",
    year = "2016",
    month = "4",
    day = "1",
    doi = "10.1111/myc.12452",
    language = "English (US)",
    volume = "59",
    pages = "226--233",
    journal = "Mycoses",
    issn = "0933-7407",
    publisher = "Wiley-Blackwell",
    number = "4",

    }

    TY - JOUR

    T1 - Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections

    AU - Pham, Aaron N.

    AU - Bubalo, Joseph

    AU - Lewis, James S.

    PY - 2016/4/1

    Y1 - 2016/4/1

    N2 - Posaconazole tablet formulation (PTF) was developed to optimise bioavailability. This study compared posaconazole levels between patients on the PTF and oral suspension formulation (OSF). We also examined factors that may impact posaconazole levels. The primary and secondary objectives were analysed by comparing trough levels and attainment of target level between the formulation groups. For the 86 patients on PTF and 176 on OSF, the mean first levels was 1.32 μg ml-1 (SD = 0.69) and 0.81 μg ml-1 (SD = 0.59), P <0.0001 respectively. PTF group was more likely to achieve levels ≥0.7 μg ml-1 than OSF group (OR 7.97 [95 CI; 3.75-16.93], P <0.0001). Levels from patients on PTF and with presence of acid suppression, GI GVHD, mucositis or diarrhoea were not statistically different from those without these factors. For PTF, no correlation was found between patient's weight (kg) and levels (R2 = 0.0536, P = 0.035). The incidences of elevation in ALT/AST or Tbili were similar between the formulation groups. In conclusion, PTF should be considered the preferred formulation because it demonstrated better absorption than the OSF. Patients on PTF for prophylaxis are more likely to attain target level and may not routinely require therapeutic drug monitoring during prophylaxis.

    AB - Posaconazole tablet formulation (PTF) was developed to optimise bioavailability. This study compared posaconazole levels between patients on the PTF and oral suspension formulation (OSF). We also examined factors that may impact posaconazole levels. The primary and secondary objectives were analysed by comparing trough levels and attainment of target level between the formulation groups. For the 86 patients on PTF and 176 on OSF, the mean first levels was 1.32 μg ml-1 (SD = 0.69) and 0.81 μg ml-1 (SD = 0.59), P <0.0001 respectively. PTF group was more likely to achieve levels ≥0.7 μg ml-1 than OSF group (OR 7.97 [95 CI; 3.75-16.93], P <0.0001). Levels from patients on PTF and with presence of acid suppression, GI GVHD, mucositis or diarrhoea were not statistically different from those without these factors. For PTF, no correlation was found between patient's weight (kg) and levels (R2 = 0.0536, P = 0.035). The incidences of elevation in ALT/AST or Tbili were similar between the formulation groups. In conclusion, PTF should be considered the preferred formulation because it demonstrated better absorption than the OSF. Patients on PTF for prophylaxis are more likely to attain target level and may not routinely require therapeutic drug monitoring during prophylaxis.

    KW - Acute myeloid leukaemia

    KW - Antifungal prophylaxis

    KW - Therapeutic drug monitoring

    KW - Triazole antifungals

    UR - http://www.scopus.com/inward/record.url?scp=84960086351&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84960086351&partnerID=8YFLogxK

    U2 - 10.1111/myc.12452

    DO - 10.1111/myc.12452

    M3 - Article

    C2 - 26742659

    AN - SCOPUS:84960086351

    VL - 59

    SP - 226

    EP - 233

    JO - Mycoses

    JF - Mycoses

    SN - 0933-7407

    IS - 4

    ER -